Home Cart Sign in  
Chemical Structure| 1931994-81-8 Chemical Structure| 1931994-81-8

Structure of Zabedosertib
CAS No.: 1931994-81-8

Chemical Structure| 1931994-81-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Zabedosertib is a selective IRAK4 inhibitor with oral activity that can regulate immune responses.

Synonyms: BAY 1834845

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Zabedosertib

CAS No. :1931994-81-8
Formula : C20H21F3N4O4S
M.W : 470.47
SMILES Code : O=C(C1=NC(C(F)(F)F)=CC=C1)NC2=CC3=CN(CCS(=O)(C)=O)N=C3C=C2C(C)(O)C
Synonyms :
BAY 1834845
MDL No. :MFCD32900903

Safety of Zabedosertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Zabedosertib

TLR

Isoform Comparison

Biological Activity

Description
Zabedosertib (BAY 1834845) is a selective, orally active IRAK4 inhibitor with an IC50 of 3.55 nM, showing immunomodulatory potential. IRAK4 is a kinase integral to signaling innate immune responses from Toll-like receptors [1].

In Vitro:

Cell Line
Concentration Treated Time Description References
Human peripheral blood mononuclear cells (hPBMC) 500 nM 20 hours Detection of the release of 48 cytokines. Both BAY-1834845 and PF-06650833 effectively reduced the secretion of inflammatory cytokines such as IL-1, IFN-γ, TNF-α, and IL-17. Biomed Pharmacother. 2022 Sep;153:113459.
human peripheral blood mononuclear cells (hPBMC) 500 nmol/L 20 hours To evaluate the effect of PF-06650833 on inflammatory cytokine secretion after LPS stimulation. Results showed PF-06650833 effectively reduced the secretion of inflammatory cytokines such as IL-1, IFN-γ, TNF-α, and IL-17. Biomed Pharmacother. 2022 Sep;153:113459

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice IL-1β-induced inflammation model Oral 10 and 40 mg/kg Single dose BAY1830839 and BAY1834845 significantly and dose-dependently reduced the levels of IL-6 and TNF-α J Med Chem. 2024 Jan 25;67(2):1225-1242
Female Balb/c mice LPS-induced ARDS mouse model Oral 150 mg/kg Preventive administration: one dose 30 min before modeling and another consolidation dose 6h later; Therapeutic administration: two doses at 4 h and 12 h after modeling. Evaluation of the therapeutic effects of IRAK4 inhibitors on ARDS. BAY-1834845 significantly reduced lung inflammation and neutrophil infiltration, improved lung injury scores, while PF-06650833 showed minimal effects. Dexamethasone had some effects but was less significant than BAY-1834845. Biomed Pharmacother. 2022 Sep;153:113459.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.63mL

2.13mL

1.06mL

21.26mL

4.25mL

2.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories